PRINCETON, N.J., Oct. 21 -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical,biotechnology, generic drug and medical device companies, today announced its participation at the 8th Annual Partnerships in Clinical Trials Conference taking place at the World Trade Center in Rotterdam, The Netherlands
At the conference, top management will discuss some of the most important issues to impact the industry growth and financial performance of CROs and their clients: the changing marketplace for drug development services, the industry's move to the fast growing emerging markets, and the clinical implications of developing biosimilar therapeutics.
Wednesday, 4 November 2009
Jeffrey P. McMullen, President and CEO of PharmaNet Development Group, will give a keynote presentation, "CRO Growth Opportunities in a More Challenging Market Environment."
Dr. Robert Reekie, Senior Executive Vice President Operations, Europe, Asia-Pacific, will chair a session entitled "Emerging Economies – Your Strategic Expansion for Cost Reduction and Patient Recruitment."
Thursday, 5 November 2009
Dr. Pablo Fernandez, Senior Vice President, Medical Affairs, will present "A Practical Overview of Outsourced Clinical Development for Biosimilars."
Conference attendees are invited to visit booth number 94 where PharmaNet Development Group's international team of experts will discuss how the Company helps clients reach their goal of delivering safe and effective therapeutics to patients.
About PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com .
SOURCE PharmaNet Development Group, Inc.
Subscribe to our Free Newsletters!
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...View All